Skip to main content
OpenTrials

Clinical trial condition

Geographic Atrophy

Explore clinical trials studying Geographic Atrophy. Study availability and eligibility vary by location and protocol.

137 public trials 32 recruiting studies
Refine in advanced search Browse all conditions

Geographic Atrophy trial results

Completed

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

NCT03815825

Conditions
Eye Diseases, Geographic Atrophy, Macular Degeneration, +2 more
Locations
  • IONIS Investigative Site Phoenix, Arizona, United States
  • IONIS Investigative Site Phoenix, Arizona, United States
  • IONIS Investigative Site Phoenix, Arizona, United States
  • IONIS Investigative Site Sun City, Arizona, United States
View all 88 locations
View Trial Details
Completed

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06006585

Conditions
Eye Diseases, Geographic Atrophy, Macular Degeneration, +2 more
Locations
  • Bay Area Retina Associates - Walnut Creek Walnut Creek, California, United States
  • Florida Retina Institute Jacksonville, Florida, United States
  • Florida Eye Associates Melbourne, Florida, United States
  • Verum Research, LLC Eugene, Oregon, United States
View Trial Details
Completed

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

NCT04744662

Conditions
Eye Diseases, Geographic Atrophy, Macular Degeneration, +2 more
Locations
  • Chatswood Retina Chatswood, New South Wales, Australia
  • Retina and Eye Consultants Hurtsville Hurstville, New South Wales, Australia
  • Retinology Institute Glen Iris, Victoria, Australia
  • Queensland Eye Institute Melbourne, Victoria, Australia
View Trial Details
Completed

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

NCT04264819

Conditions
Cardiovascular Diseases, Choroid Diseases, Choroidal Neovascularization, +22 more
Locations
  • Novartis Investigative Site Nice, Cedex1, France
  • Novartis Investigative Site Rennes, FRA, France
  • Novartis Investigative Site Saint-Cyr-sur-Loire, Indre Et Loire, France
  • Novartis Investigative Site Lyon, Rhone, France
View all 51 locations
View Trial Details
Completed

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

NCT02463344

Conditions
Age-Related Macular Degeneration, Eye Diseases, Geographic Atrophy, +3 more
Locations
  • Jules Stein Eye Institute, UCLA School of Medicine Los Angeles, California, United States
  • Bascom Palmer Eye Institute Miami, Florida, United States
  • Mass Eye and Ear Boston, Massachusetts, United States
  • Wills Eye Institute-Mid Atlantic Retina Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration

NCT01344993

Conditions
Dry Age Related Macular Degeneration, Eye Diseases, Geographic Atrophy, +3 more
Locations
  • Jules Stein Eye Institute, UCLA School of Medicine Los Angeles, California, United States
  • Bascom Palmer Eye Institute Miami, Florida, United States
  • Mass Eye and Ear Boston, Massachusetts, United States
  • Wills Eye Institute-Mid Atlantic Retina Philadelphia, Pennsylvania, United States
View Trial Details
Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

NCT04597632

Conditions
Choroid Diseases, Choroidal Neovascularization, Eye Diseases, +16 more
Locations
  • Novartis Investigative Site Huntington Beach, California, United States
  • Novartis Investigative Site Fort Lauderdale, Florida, United States
  • Novartis Investigative Site Indianapolis, Indiana, United States
  • Novartis Investigative Site Minneapolis, Minnesota, United States
View all 60 locations
View Trial Details
Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352

Conditions
Age-Related Macular Degeneration, Choroid Diseases, Choroidal Neovascularization, +17 more
Locations
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Huntington Beach, California, United States
  • Novartis Investigative Site Loma Linda, California, United States
  • Novartis Investigative Site Riverside, California, United States
View all 118 locations
View Trial Details

Related conditions